App-Quantinova.ai

Do Fatty Lesions Explain the Association Between Inflammation and New Syndesmophytes in Patients with Radiographic Axial Spondyloarthritis?

Rosalinde Stal - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA Criteria Are Met?

Laura Coates - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

N/A

Dose-dependent Suppression of T Cell-Dependent Antibody Response in Healthy Volunteers by KPL-404, an Anti-CD40 Monoclonal Antibody, Supports Phase 2 Study in Patients with Rheumatoid Arthritis

Lara Pupim - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Dynamics of Nail Psoriasis with Guselkumab Treatment and Withdrawal in Association with Skin Response and Patient-reported Outcomes Based on a post Hoc Analysis of Clinical Trial Data

William Tillett - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

guselkumab (IV)

Early Clinical Improvement as Predictor of Long-term Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Guselkumab: Post Hoc Analysis Through 2 Years of a Phase 3 Study

Iain B McInnes - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

guselkumab (IV)

Early Skin and Early Enthesitis Responses in Psoriatic Arthritis Patients Treated with Guselkumab Associate with Long-term Response: Post Hoc Analysis Through 2 Years of a Phase 3 Study

Laura Coates - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

guselkumab (IV)

Educational Needs Among Health Professionals in Rheumatology: Low Awareness of EULAR Offerings and Unfamiliarity with Course Content as a Major Barrier – a EULAR Funded European Survey

Lisa Sperl - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Posterior Reversible Encephalopathy Syndrome

N/A

Effect of Atacicept on Renal Function in Patients with Systemic Lupus Erythematosus (SLE)

David Isenberg - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Lupus

N/A

Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE)

Jason S Knight - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Belimumab

Effect of Filgotinib on Body Weight and BMI and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in RA

Alejandro Balsa - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Filgotinib

Effect of Romosozumab in Postmenopausal Women with Knee Osteoarthritis: Results from the FRAME Clinical Trial

Nancy Lane - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Knee osteoarthritis

Romosozumab

Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study

Xenofon Baraliakos - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Axial spondyloarthritis

Adalimumab biosimilar

Effect of Upadacitinib, Adalimumab, and Placebo on Residual Pain Among Patients with Rheumatoid Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment

Louis Bessette - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

ABT-494

Effects of Treatment with Risankizumab on Minimal Disease Activity and Disease Activity in Psoriatic Arthritis: An Analysis of the KEEPsAKE-1 and -2 Trials

Joseph Merola - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

Risankizumab

Efficacy and Improvement in Patient-Reported Outcomes at Weeks 16 and 52 in Ixekizumab Treated Biological Naïve Patients with Radiographic Axial Spondyloarthritis Achieving Clinically Important Pain at Night Reduction at Week 16: Results from COAST-V Trial

Sofia Ramiro - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

Adalimumab

Efficacy and Safety of Allopurinol and Febuxostat in Patients with Gout and Chronic Kidney Disease: A Subgroup Analysis of the STOP Gout Study

Lindsay Helget - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

Allopurinol

Efficacy and Safety of Biological DMARDs: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis

Casper Webers - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Efficacy and Safety of Cenerimod in Patients with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2b Trial

David D'Cruz - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Efficacy and Safety of Filgotinib in Patients with Inadequate Response to Methotrexate, with 4 or < 4 Poor Prognostic Factors: A Post Hoc Analysis of the FINCH 1 Study

BERNARD COMBE - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Methotrexate

Efficacy and Safety of Non-Pharmacological and Non-Biological Therapy: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis

Augusta Ortolan - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Filters

45280 Abstracts